Global Pharma Titans Commit Billions to U.S. Manufacturing Surge

Pfizer is spearheading this shift with a $70 billion commitment directed toward research, development, and expanded domestic manufacturing facilities, a move formalized under an agreement with President Donald Trump. AstraZeneca is matching this intensity with a $50 billion investment earmarked for completion by 2030, representing the company’s most ambitious single-site project to date.

These capital injections serve a dual purpose: insulating operations against global supply-chain volatility and satisfying investor demand for a firmer foothold in the American market. Beyond the infrastructure upgrades, the expansion is expected to create thousands of specialized jobs, effectively cementing the United States as the primary hub for international pharmaceutical innovation.